Cargando…

Tumor Necrosis Factor’s Pathway in Crohn’s Disease: Potential for Intervention

Crohn’s disease (CD) is a chronic disorder characterized by full thickness patchy inflammation of the gastrointestinal tract. The pathogenesis is multifactorial and involves defective innate immune responses, microbiome alterations, and dysregulated activation of the acquired component of mucosal im...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pagnini, Cristiano, Cominelli, Fabio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8508644/ https://www.ncbi.nlm.nih.gov/pubmed/34638616 http://dx.doi.org/10.3390/ijms221910273

Ejemplares similares

Novel Pharmacological Therapy in Inflammatory Bowel Diseases: Beyond Anti-Tumor Necrosis Factor
por: Pagnini, Cristiano, et al.
Publicado: (2019)

Genetic Dissection of the Cellular Pathways and Signaling Mechanisms in Modeled Tumor Necrosis Factor–induced Crohn's-like Inflammatory Bowel Disease
por: Kontoyiannis, Dimitris, et al.
Publicado: (2002)

Preoperative use of anti-tumor necrosis factor therapy in Crohn's disease: promises and pitfalls
por: Kotze, Paulo Gustavo, et al.
Publicado: (2017)

Correlation of serum levels of anti-tumor necrosis factor agents with perianal fistula healing in Crohn’s disease: a narrative review
por: Miranda, Eron Fabio, et al.
Publicado: (2021)

Systematic Review with Network Meta-Analysis: Efficacy of Induction Therapy with a Second Biological Agent in Anti-TNF-Experienced Crohn's Disease Patients
por: Pagnini, Cristiano, et al.
Publicado: (2018)

Uncovering Pathogenic Mechanisms of Inflammatory Bowel Disease Using Mouse Models of Crohn’s Disease–Like Ileitis: What is the Right Model?
por: Cominelli, Fabio, et al.
Publicado: (2017)

Anti-tumor Necrosis Factor Therapy for Crohn Disease: Friend or Foe to the Surgeon?
por: Kim, Hungdai
Publicado: (2015)

Use of Vitamin D With Anti-Tumor Necrosis Factor Therapy for Crohn’s Disease
por: Bafutto, Mauro, et al.
Publicado: (2020)

Tumor Necrosis Factor-alpha Antibodies in Fistulizing Crohn's Disease: An Updated Systematic Review and Meta-analysis
por: Zaboli, Pardis, et al.
Publicado: (2017)

TWEAK/Fn14 Is Overexpressed in Crohn’s Disease and Mediates Experimental Ileitis by Regulating Critical Innate and Adaptive Immune Pathways
por: Di Martino, Luca, et al.
Publicado: (2019)

Factors associated with anti-tumor necrosis factor effectiveness to prevent postoperative recurrence in Crohn’s disease
por: Buisson, Anthony, et al.
Publicado: (2022)

Paradoxical Arthralgia Secondary to Anti-Tumor-Necrosis-Factor Alpha Therapy in Crohn’s Disease
por: Thurlapati, Aswani, et al.
Publicado: (2021)

Could Early Anti-Tumor Necrosis Factor Therapy Change the Prognosis of Crohn's Disease?
por: Ye, Byong Duk
Publicado: (2014)

Genetic polymorphisms predict response to anti-tumor necrosis factor treatment in Crohn’s disease
por: Netz, Uri, et al.
Publicado: (2017)

Tumor necrosis factor-α antibodies (infliximab, adalimumab and certolizumab) in Crohn's disease: systematic review and meta-analysis
por: Kawalec, Paweł, et al.
Publicado: (2013)

Targeting tumor-necrosis factor receptor pathways for tumor immunotherapy
por: Schaer, David A, et al.
Publicado: (2014)

Endoscopic response to tumor necrosis factor inhibitors predicts long term benefits in Crohn’s disease
por: Alfaro, Ignacio, et al.
Publicado: (2019)

The Efficacy of Anti-Tumor Necrosis Factor Alpha for Symptomatic Stricturing Small Bowel Crohn’s Disease
por: Alourfi, Mansour, et al.
Publicado: (2020)

Continued Postoperative Use of Tumor Necrosis Factor-α Inhibitors for the Prevention of Crohn’s Disease Recurrence
por: Yu, Jongwook, et al.
Publicado: (2022)

Bronchoesophageal fistula in a patient with Crohn’s disease receiving anti-tumor necrosis factor therapy
por: Oh, Kyunghwan, et al.
Publicado: (2023)

Tumour necrosis factor inhibitors in Crohn's disease and the effect on surgery rates
por: Eberhardson, Michael, et al.
Publicado: (2022)

Long‐term outcomes of anti‐tumor necrosis factor therapy and surgery in nonperianal fistulizing Crohn's disease
por: Vuyyuru, Sudheer K, et al.
Publicado: (2021)

Altered pattern of tumor necrosis factor-alpha production in peripheral blood monocytes from Crohn's disease
por: Loganes, Claudia, et al.
Publicado: (2016)

Growth and Adult Height in Patients with Crohn's Disease Treated with Anti-Tumor Necrosis Factor α Antibodies
por: Bamberger, Sarah, et al.
Publicado: (2016)

Efficacy of restarting anti-tumor necrosis factor α agents after surgery in patients with Crohn's disease
por: Hiraoka, Sakiko, et al.
Publicado: (2018)

Tumor necrosis factor α-induced protein 3 (A20) is dysregulated in pediatric Crohn disease
por: Zaidi, Deenaz, et al.
Publicado: (2018)

The Long-Term Effect of Early Anti-Tumor Necrosis Factor on Restoration of Growth in Pediatric Crohn’s Disease
por: Shim, Jung Ok, et al.
Publicado: (2018)

The Effect of Adiposity on Anti–Tumor Necrosis Factor-Alpha Levels and Loss of Response in Crohn's Disease Patients
por: Lim, Zixiang, et al.
Publicado: (2020)

A Series of Genes for Predicting Responses to Anti-Tumor Necrosis Factor α Therapy in Crohn’s Disease
por: Nie, Kai, et al.
Publicado: (2022)

Tumor necrosis factor receptor-mediated signaling pathways
Publicado: (1994)

Therapeutic Drug Monitoring of Tumor Necrosis Factor Antagonists in Crohn Disease: A Theoretical Construct to Apply Pharmacokinetics and Guidelines to Clinical Practice
por: Vande Casteele, Niels, et al.
Publicado: (2020)

Pulmonary Tuberculosis After Therapy with Anti-Tumor Necrosis Factor (TNF) for Crohn Disease: A Case Report
por: da Silva, Douglas Inomata Cardoso, et al.
Publicado: (2021)

Rare and Serious Adverse Effects of Anti-Tumor Necrosis Factor-Alpha (TNF-α) Agents in Crohn’s Disease
por: Kim, Sun, et al.
Publicado: (2021)

Real world analysis on the efficacy and safety of anti-tumor necrosis factor therapy in patients with stricturing Crohn’s disease
por: Vuyyuru, Sudheer K., et al.
Publicado: (2021)

New Onset, Aggravation and Recurrence of Crohn's Disease upon Treatment with Three Different Tumor Necrosis Factor Inhibitors
por: Zeitz, Jonas, et al.
Publicado: (2015)

Tofacitinib for the treatment of tumor necrosis factor-α inhibitor refractory esophageal Crohn’s disease: a case report
por: Nathoo, Sunina, et al.
Publicado: (2016)

Defining and predicting deep remission in patients with perianal fistulizing Crohn’s disease on anti-tumor necrosis factor therapy
por: Papamichael, Konstantinos, et al.
Publicado: (2017)

Novel candidate drugs in anti-tumor necrosis factor refractory Crohn’s diseases: in silico study for drug repositioning
por: Kwak, Min Seob, et al.
Publicado: (2020)

Comparison of mucosa-associated microbiota in Crohn’s disease patients with and without anti-tumor necrosis factor-α therapy
por: Fukushima, Shinya, et al.
Publicado: (2022)

Enrichment of Activated Fibroblasts as a Potential Biomarker for a Non-Durable Response to Anti-Tumor Necrosis Factor Therapy in Patients with Crohn’s Disease
por: Park, Soo-Kyung, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_tj4v0ecar7pc4d6imgvkdj9kl2